Premium
9p21 deletion correlates with recurrence in head and neck cancer
Author(s) -
Lydiatt William M.,
Davidson Bruce J.,
Schantz Stimson P.,
Caruana Salvatore,
Chaganti Raju S. K.
Publication year - 1998
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/(sici)1097-0347(199803)20:2<113::aid-hed3>3.0.co;2-5
Subject(s) - loss of heterozygosity , head and neck squamous cell carcinoma , cancer research , biology , tumor suppressor gene , carcinogenesis , head and neck cancer , cancer , gene , genetics , allele
Background Deletion of 9p21 is a common event in many human tumors, including head and neck squamous cell carcinoma (HNSCC). The gene CDKN2, which encodes the protein p16, a cyclin‐dependent kinase‐4 inhibitor, maps to 9p21. The role of CDKN2 as the tumor suppressor gene in these neoplasms is unclear. The role of loss of heterozygosity (LOH) as a prognostic tool has not been described in HNSCC. Methods We performed deletion mapping using Southern and PCR‐based LOH analysis and prospective survival analysis. Results We demonstrate that LOH of 9p and, specifically, the interferon (IFN) gene cluster correlates with recurrence of HNSCC. We also demonstrate two separate areas of deletion on 9p, one centromeric to IFNβ and telomeric to CDKN2 and the other centromeric to CDKN2 and telomeric to the polymorphic marker D9S19. All the deletions involve either the markers IFNα and/or D9S171 and D9S126 but not necessarily CDKN2. Conclusions These results suggest another tumor suppressor gene (TSG) may be involved in HNSCC carcinogenesis and may play a role in aggressive disease as manifest by local, regional, or distant recurrence. © 1998 John Wiley & Sons, Inc. Head Neck 20: 113–118, 1998.